Tallac Therapeutics doses first subject in Phase I/II solid tumour trial
The trial will assess the pharmacokinetics, safety, and the preliminary anti-tumour activity of TAC-001 to treat solid tumours.
Procaps WP
Ascletis Pharma doses first subject in HIV treatment trial
Halia doses first subject in Phase I trial of chronic inflammation asset
Prothione capsules reduce Covid-19 viral load in Phase II trial
Aerie doses first participant in Phase III dry eye disease therapy trial
A fourth Covid-19 booster dose may be needed to prevent a return to ‘pandemic phase’
Vaxxinity doses first subject in Phase III Covid-19 booster vaccine trial
Freeline Therapeutics doses first subject in haemophilia B therapy trial
